These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11296138)

  • 41. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients.
    Allen-Auerbach M; de Vos S; Czernin J
    Radiol Clin North Am; 2008 Mar; 46(2):199-211, vii. PubMed ID: 18619376
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Perspectives of molecular imaging and radioimmunotherapy in lymphoma.
    Iagaru A; Goris ML; Gambhir SS
    Radiol Clin North Am; 2008 Mar; 46(2):243-52, viii. PubMed ID: 18619379
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest.
    Bangerter M; Kotzerke J; Griesshammer M; Elsner K; Reske SN; Bergmann L
    Acta Oncol; 1999; 38(6):799-804. PubMed ID: 10522771
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients.
    Abdulqadhr G; Molin D; Aström G; Suurküla M; Johansson L; Hagberg H; Ahlström H
    Acta Radiol; 2011 Mar; 52(2):173-80. PubMed ID: 21498346
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
    Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y
    Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma.
    Moog F; Kotzerke J; Reske SN
    J Nucl Med; 1999 Sep; 40(9):1407-13. PubMed ID: 10492357
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 18F-FDG PET in malignant lymphoma: significance of positive findings.
    Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin's lymphoma.
    Tatsumi M; Kitayama H; Sugahara H; Tokita N; Nakamura H; Kanakura Y; Nishimura T
    J Nucl Med; 2001 Apr; 42(4):601-8. PubMed ID: 11337549
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Negative gallium-67 citrate and positive positron emission tomography/computed tomography spleen scans, in Hodgkin's stage IV lymphoma.
    Malamitsi J; Kosmidis H; Valotassiou B; Bonou I; Andreou J
    Hell J Nucl Med; 2007; 10(2):116-8. PubMed ID: 17684589
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [18F]-FDG positron imaging in clinical management of lymphoma patients.
    Talbot JN; Haioun C; Rain JD; Meignan M; Wioland M; Misset JL; Grahek D; Kerrou K; Montravers F
    Crit Rev Oncol Hematol; 2001 Jun; 38(3):193-221. PubMed ID: 11369254
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma?
    Fuster D; Chiang S; Andreadis C; Guan L; Zhuang H; Schuster S; Alavi A
    Nucl Med Commun; 2006 Jan; 27(1):11-5. PubMed ID: 16340718
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Functional imaging of Hodgkin's disease with FDG-PET and gallium-67.
    Willkomm P; Palmedo H; Grünwald F; Ruhlmann J; Biersack HJ
    Nuklearmedizin; 1998; 37(7):251-3. PubMed ID: 9830616
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of PET and PET/CT in managing the care of lymphoma patients.
    Evans WC; Gilmore D; English J
    J Nucl Med Technol; 2011 Sep; 39(3):190-4. PubMed ID: 21795369
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma.
    Zijlstra JM; Hoekstra OS; Raijmakers PG; Comans EF; van der Hoeven JJ; Teule GJ; Jonkhoff AR; v Tinteren H; Lammertsma AA; Huijgens PC
    Br J Haematol; 2003 Nov; 123(3):454-62. PubMed ID: 14617005
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical value of FDG PET using coincident gamma cameras in staging and restaging of malignant lymphoma--compared with convenitonal diagnostic methods].
    Pichler R; Maschek W; Hatzl-Griesenhofer M; Huber H; Wimmer G; Wahl G; Fridrik M
    Nuklearmedizin; 2000 Sep; 39(6):166-73. PubMed ID: 11057408
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas.
    Kumar R; Maillard I; Schuster SJ; Alavi A
    Radiol Clin North Am; 2004 Nov; 42(6):1083-100. PubMed ID: 15488559
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
    Cremerius U; Fabry U; Neuerburg J; Zimny M; Bares R; Osieka R; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935
    [TBL] [Abstract][Full Text] [Related]  

  • 59. FDG PET/CT versus CT, MR imaging, and 67Ga scintigraphy in the posttherapy evaluation of malignant lymphoma.
    Okada M; Sato N; Ishii K; Matsumura K; Hosono M; Murakami T
    Radiographics; 2010; 30(4):939-57. PubMed ID: 20631361
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of
    Kaste SC; Snyder SE; Metzger ML; Sandlund JT; Howard SC; Krasin M; Shulkin BL
    J Nucl Med; 2017 Mar; 58(3):419-424. PubMed ID: 27609791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.